The National Institute for Health and Care Excellence has published its final appraisal determination recommending Kyprolis (carfilzomib, Amgen Inc.) in combination with dexamethasone as an option for treating adults with relapsed multiple myeloma (RMM) who have received one prior therapy that does not include Velcade (bortezomib, Takeda Oncology Co.).